当前位置:首页 - 行情中心 - 多瑞医药(301075) - 财务分析 - 现金流量表

多瑞医药

(301075)

  

流通市值:23.17亿  总市值:32.74亿
流通股本:5660.00万   总股本:8000.00万

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金177,318,562.34121,044,931.6543,172,346.3186,567,606.94
  收到的税费返还96,605.4896,605.48--
  收到其他与经营活动有关的现金10,124,852.716,116,175.92433,912.7810,915,666.37
  经营活动现金流入小计187,540,020.53127,257,713.0543,606,259.08197,483,273.31
  购买商品、接受劳务支付的现金152,306,407.36113,920,424.5148,492,059.79104,915,236.1
  支付给职工以及为职工支付的现金51,968,03135,505,529.9919,780,310.473,107,715.41
  支付的各项税费6,295,655.585,216,193.75693,111.338,823,054.45
  支付其他与经营活动有关的现金41,064,884.6117,049,518.8911,293,284.9656,469,695.94
  经营活动现金流出小计251,634,978.55171,691,667.1480,258,766.48243,315,701.9
  经营活动产生的现金流量净额-64,094,958.02-44,433,954.09-36,652,507.4-45,832,428.59
二、投资活动产生的现金流量:
  收回投资收到的现金27,000,00027,000,00025,000,000921,983,000
  取得投资收益收到的现金344,536.4344,536.4144,480.473,277,925.67
  处置固定资产、无形资产和其他长期资产收回的现金净额560,000560,000408,817.6775,996.59
  处置子公司及其他营业单位收到的现金净额92,955,355.0928,150,594.72-8,800,000
  收到的其他与投资活动有关的现金76,946,613.842,420,834.48-252,899,763.19
  投资活动现金流入小计197,806,505.2998,475,965.625,553,298.071,187,736,685.45
  购建固定资产、无形资产和其他长期资产支付的现金85,154,697.763,896,424.7942,696,360.19101,816,834.99
  投资支付的现金155,000,0005,000,0005,000,000812,987,000
  支付其他与投资活动有关的现金---100,348,060.5
  投资活动现金流出小计240,154,697.768,896,424.7947,696,360.191,015,151,895.49
  投资活动产生的现金流量净额-42,348,192.4129,579,540.81-22,143,062.12172,584,789.96
三、筹资活动产生的现金流量:
  取得借款收到的现金189,140,429.13--127,700,000
  收到其他与筹资活动有关的现金76,403,810.3276,403,810.3256,442,970.07180,000
  筹资活动现金流入小计265,544,239.4576,403,810.3256,442,970.07127,880,000
  偿还债务支付的现金85,900,00077,700,00016,000,000183,909,096
  分配股利、利润或偿付利息支付的现金3,616,764.412,641,826.41,481,267.238,789,100.15
  支付其他与筹资活动有关的现金1,978,952.941,562,686.3-86,774,994.34
  筹资活动现金流出小计91,495,717.3581,904,512.717,481,267.23279,473,190.49
  筹资活动产生的现金流量净额174,048,522.1-5,500,702.3838,961,702.84-151,593,190.49
四、汇率变动对现金及现金等价物的影响----1,462.29
五、现金及现金等价物净增加额67,605,371.67-20,355,115.66-19,833,866.68-24,842,291.41
  加:期初现金及现金等价物余额85,276,030.585,276,030.585,278,030.5110,118,321.91
  期末现金及现金等价物余额152,881,402.1764,920,914.8465,444,163.8285,276,030.5
补充资料:
  净利润-3,240,666.51--132,401,390.23
  资产减值准备--2,143,241.49-5,992,360.28
  固定资产和投资性房地产折旧-23,796,357.06-46,959,981.83
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-23,796,357.06-46,959,981.83
  无形资产摊销-1,467,408-2,194,957.39
  长期待摊费用摊销-139,991.3-318,955.98
  处置固定资产、无形资产和其他长期资产的损失--242,762.47-105,451.29
  固定资产报废损失---827,649.25
  公允价值变动损失----38,583.78
  财务费用-6,603,947.79-17,937,693.71
  投资损失--40,205,255.59--852,610.79
  递延所得税-2,929,245.07--647,307.09
  其中:递延所得税资产减少-3,052,813.85--400,169.55
    递延所得税负债增加--123,568.78--247,137.54
  存货的减少--29,591,348.16--43,511,247.61
  经营性应收项目的减少--20,584,585.3-16,288,110.96
  经营性应付项目的增加-9,001,236.34-25,996,601.96
  其他---11,837,463.65
  现金的期末余额-64,920,914.84-85,276,030.5
  减:现金的期初余额-85,276,030.5-110,118,321.91
  现金及现金等价物的净增加额--20,355,115.66--24,842,291.41
公告日期2026-10-292026-08-262026-04-292026-04-29
审计意见(境内)标准无保留意见
TOP↑